Cross-Sector entity
Apogee Therapeutics is most often covered alongside Arcturus Therapeutics, which appears in 3 of these 4 stories. The 132-day window averages about 0.2 stories each week. The busiest single day carried 3. The clearest coverage concentration is pharma: 2 of 4 stories, with the rest divided among 2 other categories.
4 verified stories tracked
Last mentioned: Jul 28, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Apogee Therapeutics is most often covered alongside Arcturus Therapeutics, which appears in 3 of these 4 stories. The 132-day window averages about 0.2 stories each week. The busiest single day carried 3. The clearest coverage concentration is pharma: 2 of 4 stories, with the rest divided among 2 other categories. Apogee Therapeutics appears in 4 tracked Cross-Sector stories published from March 19, 2026 through July 28, 2026. Each carries 2 original sources on average.
Computed from the 4 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Apogee Therapeutics. Shared-story counts are live from our verified record — not editorial picks.
AbbVie's second-quarter results, expected to show $3.61 EPS, hinge on the continued clinical and commercial success of Rinvoq and Skyrizi. The Apogee deal underscores a deepening immunology pipeline as Humira fades into the rearview.
Source: The Motley Fool · Thomas Niel (us)
A significant wave of analyst rating changes has hit the market, featuring a notable downgrade for boutique fitness giant Xponential Fitness and a bullish initiation for space leader Rocket Lab. These shifts underscore a broader institutional reassessment of growth trajectories across the fitness, aerospace, and biotechnology sectors.
Apogee Therapeutics and Arcturus Therapeutics experienced a wave of conflicting analyst activity on Thursday, with both companies facing significant downgrades alongside new initiations. This institutional tug-of-war highlights the increasing volatility and selective nature of investment in mid-cap biotechnology firms.
Apogee Therapeutics and Arcturus Therapeutics faced simultaneous downgrades and initiations in a single trading session, highlighting a sharp divide in analyst sentiment. This volatility reflects broader market uncertainty regarding clinical-stage biotech valuations and the specific pipelines of these immunology and mRNA specialists.
Source: benzinga.com · benzinga.com
